title: Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 Study.
abstract: OBJECTIVE
  We conducted a phase III study to compare the survival impact of concurrent versus sequential treatment with radiotherapy (RT) and chemotherapy (CT) in unresectable stage III non-small-cell lung cancer (NSCLC).
  
  
  METHODS
  Patients were randomly assigned to one of the two treatment arms. In the sequential arm, patients received induction CT with cisplatin (120 mg/m2) on days 1, 29, and 57, and vinorelbine (30 mg/m2/wk) from day 1 to day 78, followed by thoracic RT at a dose of 66 Gy in 33 fractions (2 Gy per fraction and 5 fractions per week). In the concurrent arm, the same RT was started on day 1 with two concurrent cycles of cisplatin 20 mg/m2/d and etoposide 50 mg/m2/d (days 1 to 5 and days 29 to 33); patients then received consolidation therapy with cisplatin 80 mg/m2 on days 78 and 106 and vinorelbine 30 mg/m2/wk from days 78 to 127.
  
  
  RESULTS
  Two hundred five patients were randomly assigned. Pretreatment characteristics were well balanced between the two arms. There were six toxic deaths in the sequential arm and 10 in the concurrent arm. Median survival was 14.5 months in the sequential arm and 16.3 months in the concurrent arm (log-rank test P = .24). Two-, 3-, and 4-year survival rates were better in the concurrent arm (39%, 25%, and 21%, respectively) than in the sequential arm (26%, 19%, and 14%, respectively). Esophageal toxicity was significantly more frequent in the concurrent arm than in the sequential arm (32% v 3%).
  
  
  CONCLUSIONS
  Although not statistically significant, clinically important differences in the median, 2-, 3-, and 4-year survival rates were observed, with a trend in favor of concurrent chemoradiation therapy, suggesting that is the optimal strategy for patients with locally advanced NSCLC.
authors.affiliation: University Hospital, Saint-Etienne Cedex 2, France. pierre.fournel@chu-st-etienne.fr
authors.forename: Pierre
authors.initials: P
authors.lastname: Fournel
authors.forename: Gilles
authors.initials: G
authors.lastname: Robinet
authors.forename: Pascal
authors.initials: P
authors.lastname: Thomas
authors.forename: Pierre-Jean
authors.initials: PJ
authors.lastname: Souquet
authors.forename: Hervé
authors.initials: H
authors.lastname: Léna
authors.forename: Alain
authors.initials: A
authors.lastname: Vergnenégre
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Delhoume
authors.forename: Jacques
authors.initials: J
authors.lastname: Le Treut
authors.forename: Jules-Antoine
authors.initials: JA
authors.lastname: Silvani
authors.forename: Eric
authors.initials: E
authors.lastname: Dansin
authors.forename: Marie-Cécile
authors.initials: MC
authors.lastname: Bozonnat
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Daurés
authors.forename: Françoise
authors.initials: F
authors.lastname: Mornex
authors.forename: Maurice
authors.initials: M
authors.lastname: Pérol
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D019583:Dose Fractionation, Radiation; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine
chemical_list: D014747:Vinblastine; D002945:Cisplatin; D000077235:Vinorelbine